Antibiotic susceptibility testing: Present and future

Pediatric Infectious Disease Journal

Volumn 34, Issue 10, 2015, Pages 1128-1130

  Arena, Fabio ^a   Viaggi, Bruno ^b   Galli, Luisa ^c,d   Rossolini, Gian Maria ^a,b,e,f  

^a UNIVERSITY OF SIENA   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

^f IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

Antimicrobial agents; Molecular antibiogram; Phenotypic antibiogram; Susceptibility testing

Indexed keywords

BETA LACTAMASE; CARBAPENEM; CARBAPENEMASE; PIPERACILLIN PLUS TAZOBACTAM;

AGAR DILUTION; ANTIBIOTIC SENSITIVITY; BACTERIAL GROWTH; BACTERIUM COLONY; BLOOD CULTURE; BROTH DILUTION; CLINICAL PRACTICE; DNA SEQUENCE; GROWTH CURVE; HIGH RISK PATIENT; HUMAN; IN VITRO STUDY; INCUBATION TIME; INHIBITION ZONE; INTENSIVE CARE UNIT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFERENCE VALUE; REVIEW; BACTERIAL INFECTION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY;

BACTERIAL INFECTIONS; BACTERIOLOGICAL TECHNIQUES; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84942056640     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000844     Document Type: Review

References (10)

1. MacGowan AP; BSAC Working Parties on Resistance Surveillance. Clinical implications of antimicrobial resistance for therapy. J Antimicrob Chemother. 2008;62(Suppl 2):ii105-ii114.
2. Doern G V, Vautour R, Gaudet M, et al. Clinical impact of rapid in vitro susceptibility testing and bacterial identifcation. J Clin Microbiol. 1994;32:1757-1762.
3. Bouza E, Torres M V, Radice C, et al. Direct E-test (AB Biodisk) of respiratory samples improves antimicrobial use in ventilator-associated pneumonia. Clin Infect Dis. 2007;44:382-387.
4. Arena F, Giani T, Vaggelli G, et al. Accuracy of different methods for susceptibility testing of gentamicin with KPC carbapenemase-producing Klebsiella pneumoniae. Diagn Microbiol Infect Dis. 2015;81:132-134.
5. Lat A, Clock SA, Wu F, et al. Comparison of poly-myxin B, tigecycline, cefepime, and meropenem MICs for KPC-producing Klebsiella pneumoniae by broth microdilution, Vitek 2, and Etest. J Clin Microbiol. 2011;49:1795-1798.
6. Dellinger R P, Levy MM, Rhodes A, et al; Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41:580-637.
7. Kerremans JJ, Verboom P, Stijnen T, et al. Rapid identifcation and antimicrobial susceptibility testing reduce antibiotic use and accelerate pathogen-directed antibiotic use. J Antimicrob Chemother. 2008;61:428-435.
8. Barenfanger J, Drake C, Kacich G. Clinical and fnancial benefts of rapid bacterial identifcation and antimicrobial susceptibility testing. J Clin Microbiol. 1999;37:1415-1418.
9. Galar A, Leiva J, Espinosa M, et al. Clinical and economic evaluation of the impact of rapid microbiological diagnostic testing. J Infect. 2012;65:302-309.
10. Bauer KA, Perez KK, Forrest GN, et al. Review of rapid diagnostic tests used by antimicrobial stewardship programs. Clin Infect Dis. 2014;59 Suppl 3:S134-S145.